Abstract: “Chikungunya is viral disease is transmitted to human beings by mosquito bite [2]. Chikungunya can cause fever, chills, nausea, vomiting, joint pain, head ache, and swollen in the joints. A cause of Chikungunya is mainly due to the replication of Chikungunya virus in the human body [5]. The protein E1 was used in the study which is monomer with molecular weight 50KDa which is anchored in the membrane of CHIKV. The structure of E1 was retrieved from Protein Data Bank. The PDB ID for E1 was 3N41 , which is responsible for Chikungunya virus replication. CHIKV replication is resistant to inhibition by interferon once RNA replication has been established and that CHIKV actively suppress the antiviral IFN response by preventing IFN-induced gene expression there by making host to shut-off [4,2].The report have shown that the intensity of the infection has increased with every passing year with 45%–63% attack rates in world during outbreaks India is endemic to dengue fever and due to overlappin”

Keywords: CHIKV, drug design, OSDD, E1 protein, Efavirenz , Rimantidine